184 related articles for article (PubMed ID: 30700844)
1. What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?
Zhao H; Huang XF; Gao XM; Cai H; Zhang L; Feng J; Cao XX; Zhou DB; Li J
Leukemia; 2019 Apr; 33(4):1023-1029. PubMed ID: 30700844
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of Autologous Stem Cell Transplantation in Patients with Newly Diagnosed POEMS Syndrome.
Li AA; Gao XM; Zhao H; Shen KN; Zhang L; Cao XX; Li J
Transplant Cell Ther; 2024 Feb; 30(2):207.e1-207.e7. PubMed ID: 37931801
[TBL] [Abstract][Full Text] [Related]
6. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
[TBL] [Abstract][Full Text] [Related]
7. [Autologous peripheral blood stem cell transplantation for POEMS syndrome].
Liao LS; Zheng ZH; Qu S; Wei TN; Xie Y; Lin Y; Chen BY; Chen WM
Zhonghua Nei Ke Za Zhi; 2019 Mar; 58(3):209-212. PubMed ID: 30803180
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome.
Cai QQ; Wang C; Cao XX; Cai H; Zhou DB; Li J
Eur J Haematol; 2015 Oct; 95(4):325-30. PubMed ID: 25401269
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan.
Kawajiri-Manako C; Sakaida E; Ohwada C; Miyamoto T; Azuma T; Taguchi J; Mori T; Hasegawa Y; Kondo T; Yujiri T; Yoshimitsu M; Imada K; Kurahashi S; Kahata K; Ichinohe T; Hirokawa M; Atsuta Y; Nakaseko C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1180-1186. PubMed ID: 29409882
[TBL] [Abstract][Full Text] [Related]
10. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
Tang S; Lu Y; Zhang P; Chen D; Liu X; Du X; Cao J; Ye P; Chen L; Li S; Sha K; Zhuang XX; Xie Y; Wu X; Pei R
Leuk Res; 2021 Nov; 110():106710. PubMed ID: 34619433
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
13. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
[TBL] [Abstract][Full Text] [Related]
14. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.
Li J; Huang XF; Cai QQ; Wang C; Cai H; Zhao H; Zhang L; Cao XX; Gale RP; Zhou DB
Am J Hematol; 2018 Jun; 93(6):803-809. PubMed ID: 29603764
[TBL] [Abstract][Full Text] [Related]
15. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
[TBL] [Abstract][Full Text] [Related]
16. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
17. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Goldschmidt H; Mai EK; Dürig J; Scheid C; Weisel KC; Kunz C; Bertsch U; Hielscher T; Merz M; Munder M; Lindemann HW; Hügle-Dörr B; Tichy D; Giesen N; Hose D; Seckinger A; Huhn S; Luntz S; Jauch A; Elmaagacli A; Rabold B; Fuhrmann S; Brossart P; Goerner M; Bernhard H; Hoffmann M; Hillengass J; Raab MS; Blau IW; Hänel M; Salwender HJ;
Leukemia; 2020 Jul; 34(7):1853-1865. PubMed ID: 32034285
[TBL] [Abstract][Full Text] [Related]
18. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation.
Cook G; Iacobelli S; van Biezen A; Ziagkos D; LeBlond V; Abraham J; McQuaker G; Schoenland S; Rambaldi A; Halaburda K; Rovira M; Sica S; Byrne J; Sanz RG; Nagler A; van de Donk NW; Sinisalo M; Cook M; Kröger N; De Witte T; Morris C; Garderet L
Haematologica; 2017 Jan; 102(1):160-167. PubMed ID: 27634201
[TBL] [Abstract][Full Text] [Related]
19. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
20. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome.
Li J; Zhang W; Jiao L; Duan MH; Guan HZ; Zhu WG; Tian Z; Zhou DB
Blood; 2011 Jun; 117(24):6445-9. PubMed ID: 21393478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
